Pelvalon Nominated For Medical Device Start-Up Of The Year By University Of California’s QB3 Institute For Innovation

SUNNYVALE, Calif.--(BUSINESS WIRE)--Pelvalon, a medical device company focused on developing innovative solutions for women suffering from loss of bowel control, is pleased to announce that the company has been nominated Medical Device Startup of the Year by QB3, the University of California’s premier biotech accelerator.

“Our entire team is extremely grateful for the recognition from QB3, and we look forward to celebrating the successes of all the nominees at tomorrow’s event.”

In 2000, the University of California created QB3 and three other Governor Gray Davis Institutes for Science and Innovation to drive the state’s economy and improve the quality of life for its residents. The organization partners with industry and entrepreneurial scientists to offer research facilities, educational programs, internships, mentoring, incubators, and a seed-stage venture fund. Faculty members are professors at UC Berkeley, UC Santa Cruz, and UCSF, including a Nobel laureate and 42 members of the National Academies.

The QB3 Awards recognize the highest level of achievement in life science entrepreneurship in the San Francisco Bay Area. The awards will be revealed tonight during a gala event at the California Academy of Sciences in Golden Gate Park.

“We are thrilled to be nominated for this prestigious award, especially among such esteemed fellow nominees, including ChemoFilter, Ocular Dynamics and Twelve,” said Miles Rosen, co-founder and CEO of Pelvalon. “Our entire team is extremely grateful for the recognition from QB3, and we look forward to celebrating the successes of all the nominees at tomorrow’s event.”

Pelvalon’s Eclipse System, a novel vaginal insert designed to offer a nonsurgical treatment for women suffering from loss of bowel control, was recently cleared by the U.S. Food and Drug Administration (FDA). Placed in the same location as a tampon or diaphragm, Eclipse is the first vaginal insert for bowel control. A clinical study showed demonstrated the safety and effectiveness of Eclipse in 61 women, with high efficacy (79%), an outstanding safety profile with no serious device-related adverse events, and significant improvements in quality of life.

Visit http://qb3.org to learn more about QB3’s programs, incubators, and seed-stage venture fund.

About Pelvalon

Headquartered in Sunnyvale, California, privately held Pelvalon aims to improve the lives of women who suffer from bowel control problems. Founded in 2010, Pelvalon’s groundbreaking technology originated from Stanford University’s Biodesign program, a collaboration between the schools of medicine and engineering.